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Abstract
Dengue is a significant public health concern across tropical and subtropical regions 
worldwide, principally causing disease in children. Very young children are at in-
creased risk of severe manifestations of dengue infection. The mechanism of dengue 
disease in this population is not fully understood. In this study, we present a murine 
model of dengue virus primary infection in suckling C57BL/6 and BALB/c mice in 
order to investigate disease pathogenesis. Three-day-old C57BL/6 mice intraperito-
neally infected with DENV-2 NGC were more susceptible to infection than BALB/c 
mice, showing increased liver enzymes, extended viremia, dissemination to organs 
and histological alterations in liver and small intestine. Furthermore, the immune re-
sponse in DENV-infected C57BL/6 mice exhibited a marked Th1 bias compared to 
BALB/c mice. These findings highlight the possibility of establishing an immunocom-
petent mouse model of DENV-2 infection in suckling mice that reproduces certain 
signs of disease observed in humans and that could be used to further study age-
related mechanisms of dengue pathogenesis.
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1  | INTRODUC TION
Dengue virus (DENV) is the most prevalent arthropod-transmitted 
viral infection globally, infecting an estimated 390 million people,1,2 
and causing 50-100 million apparent cases3 and 10,000 deaths an-
nually.4 Apparent cases have increased dramatically worldwide; 
more than doubling every decade since 1990,5 a trend which may 
be exacerbated by the influence of climate change and urbanization 
on vector expansion in coming decades.3,4 While infection with any 
of the four dengue serotypes (DENV 1-4) often causes subclini-
cal disease,6,7 dengue fever is a significant public health concern 
across tropical and subtropical regions.5,8 Dengue disease is asso-
ciated with high fever, myalgia and rash that may lead to potentially 
life-threatening severe dengue (SD) during defervescence, charac-
terized by thrombocytopenia, capillary leakage, bleeding, increased 
liver enzymes and complications in multiple organs.2,9 Furthermore, 
dengue disease has been associated with long-term disability.5
The most important factor for progression to SD is heterotypic 
secondary infection,10,11 though severity is ultimately determined 
by an interplay of many factors, including viral serotype,12,13 age,14 
host genetic,15,16 and immune determinants, such as cross-reactive 
T lymphocytes17,18 and serostatus.19,20 This poses a major challenge 
to vaccine design, since an incomplete or sub-optimal immune re-
sponse has the potential to prime the individual for enhanced dis-
ease upon reinfection.
Dengue affects people of all age groups, but in many parts of the 
world it is principally a pediatric public health problem.21 Particularly, 
over the last 50 years, dengue incidence has increased at a higher 
rate in infants than in any other group.22 Infants are at increased risk 
of dengue hemorrhagic manifestations and shock syndrome. The 
immaturity of infant's immune system may enhance susceptibility to 
severe dengue disease, as occurs with other severe infectious dis-
eases that are uncommon at later ages.23-25 Furthermore, maternally 
transferred antibodies have been also implicated in dengue disease 
severity.26-28 Therefore, the complex pathogenesis of dengue dis-
ease during primary infection in infants represents a major challenge 
to understand age-related mechanisms of disease.
Mouse models of disease are fundamental to understanding 
viral pathogenesis, disease progression and for preclinical testing of 
vaccines and pharmaceuticals. Murine models have been a partic-
ular challenge for DENV; traditional mouse models of primary and 
secondary infection utilize mice deficient in or fully lacking inter-
feron (IFN) or STAT receptors,29 elements whose signaling are key to 
pathogenesis in humans and vaccine responses.30,31 Newer models 
have recapitulated some aspects of disease in non-IFN-based im-
munodeficiencies or have used humanized mouse models.29 Some 
aspects of primary infection, including enzymatic and biochemical 
alterations and tissue damage have been modeled in immunocom-
petent C57BL/6 mice infected with mouse adapted-DENV and some 
clinical isolates.32-35 Another study documented increased vascular 
permeability and a platelet reduction in C57BL/6 mice infected with 
a DENV clinical isolate.36,37 Because young children are uniquely 
vulnerable to DENV infections, there has been an effort to establish 
effective murine models of enhanced disease in young mice, often 
employing infection schemes that permit the study of maternally ac-
quired antibodies.38,39
Here, we present a model establishing a baseline of detectable 
pathology after DENV primary infection in immunocompetent mice 
during the phase of exclusive suckling, with special consideration of 
technical solutions to age-specific issues in animal handling.
2  | MATERIAL S AND METHODS
2.1 | Ethics statement
The animal protocols used in this study were reviewed and approved 
by Fundación INFANT Animal Care and Use Committee (IACUC) and 
were performed according to the guidelines of the INFANT IACUC.
2.2 | Cell lines and virus preparation
Vero (African green monkey kidney) cells were grown in MEM 
(GIBCO) supplemented with 5% fetal bovine serum (FBS). The C6/36 
mosquito cell line from Aedes albopictus, adapted to grow at 33°C, 
was cultured in L-15 Medium (Leibovitz) (GIBCO) supplemented with 
0.3% tryptose phosphate broth, 0.02% glutamine, 1% MEM non-
essential amino acids solution and 5% FBS. DENV-2 strain NGC was 
grown in C6/36 cells for 4-6 days. Virus stock was titrated by plaque 
formation in Vero cells.
UV-inactivation of DENV-2 particles was performed on a Cross 
Linker XL-1500 using 5 cycles of irradiation at 3600 × 100 μJ/cm2 
dose of UV-light. Plaque assay was performed to ensure that the 
DENV particles were inactivated.
2.3 | Mouse strains and DENV infection
Five to six-week-old C57BL/6 and BALB/c breeders were obtained 
from Facultad de Ciencias Veterinarias, Universidad Nacional de la 
Plata, and housed in Fundación INFANT Animal Facility. Animals 
were housed and bred under specific pathogen-free conditions in 
individual ventilated cages, under 12/12 h of light/dark cycles, a 
temperature of 20-24°C, and a relative humidity of 40-60%. All ex-
perimental procedures were approved and were performed accord-
ing to the guidelines of the INFANT IACUC. In all experiments four 
to six mice were used per treatment group. Both male and female 
mice were used in the treatment and control groups. At least two 
independent experiments were conducted.
Suckling (3-day-old) C57BL/6 and BALB/c mice were inocu-
lated intraperitoneally (IP) with 5 × 105 PFU/g of DENV-2 NGC 
(in a maximum volume of 50 µL), or an equal volume of C6/36 
cell supernatant (control group). In order to minimize inoculum 
volume loss and contaminant entry, an inverse IP administration 
technique was used. First animal immobilization was performed by 
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the nuchal fold, followed by thorax and abdomen antisepsis with 
a cotton swab containing a povidone-iodine solution. Inoculum in-
cision was performed with a high-precision injection syringe with 
a 30G × 1/2″ needle in the subcutaneous level near the penul-
timate rib and parallel to sternum, and then moved forward into 
cranium-caudal direction in order to enter into the peritoneal 
cavity for inoculum administration. Consecutively, the syringe 
was slowly withdrawn and haemostasis was achieved with cotton 
wool. Animals were covered with bed material from original cages 
in order to mask any possible smell from manipulation before re-
turning them to cages.
Survival, cannibalism, maternal rejection and mouse weight were 
recorded at different days post-infection (PI) until 8 days PI.
2.4 | Measurement of hematological and 
biochemical parameters
Suckling mice were euthanized at 8 days PI and blood samples were 
collected in tubes containing K2-EDTA (Wiener lab). After centrif-
ugation at 2000× g for 10 minutes at room temperature, plasma 
samples were separated. Levels of alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), creatine kinase (CK), and lactate 
dehydrogenase (LDH) were measured by UV kinetics-, kinetics- or 
enzymatic- method at 8 days PI using an Architect 8100 chemistry 
analyzer (Abbott Laboratories). Platelet counts were measured by 
microscopy on a CELLDYN 3700 (Abbott Laboratories) according to 
the manufacturer´s instructions.
Transaminitis was defined as ALT and/or AST plasma values sig-
nificantly above the ones obtained for control mice. Plasma values 
of LDH and CK significantly higher than the values obtained for 
control mice were considered outcomes of disease. Platelet count 
significantly lower than the value obtained for control mice was also 
considered an outcome of disease.
2.5 | Histology
After blood collection at 8 days PI, mice were euthanized and tis-
sues (liver, kidney, spleen, small intestine, and brain) were harvested 
and immediately fixed in 10% formalin in PBS. Fixed tissues were 
embedded in paraffin, sectioned, and stained with hematoxylin and 
eosin (H&E).
2.6 | Quantitation of virus in blood and tissues by 
real time RT-PCR
Blood was extracted from suckling mice at different times (0, 17, 24, 
48, 72, 96 and 168 hours) after DENV-2 infection and collected in 
tubes containing K2-EDTA (Wiener lab.). RNA was extracted from 
plasma samples using QIAamp Viral RNA Minikit (QIAGEN) accord-
ing to the manufacturer´s instructions.
After blood extraction at the corresponding post-infection times, 
suckling mice were euthanized and the mesenteric lymph nodes as 
well as a portion of the tissues (liver, kidney, spleen, small intestine, 
and brain) were immediately snap-frozen in tubes containing a mix-
ture of dry ice/ethanol and later stored at −80°C. Total RNA was 
extracted from tissues using TRIzol (Invitrogen) according to the 
manufacturer´s instructions.
The amount of viral RNA in blood and tissues was quantified by 
using StepOnePlus Real-Time PCR System (Applied Biosystems) em-
ploying TaqMan technology, as described previously.40 Beta-actin 
was used as endogenous control. Standard curves were generated 
using 10-fold serial dilutions of viral RNA obtained from purified 
DENV-2 suspensions.
2.7 | Isolation and stimulation of spleen 
mononuclear cells
Suckling mice were infected IP with DENV-2 or inoculated with an 
equal volume of C6/36 cell supernatant (control group). At 8 days 
PI, spleens were removed from mice under sterile conditions, fol-
lowing euthanasia, and collected in tubes containing RPMI (GIBCO) 
with 10% FBS. Spleens were disrupted by grinding between two 
sterile glass slides and splenocytes were separated using a Ficoll 
gradient (GE Healthcare). Spleen mononuclear cells (1 × 106 cells/
well) were incubated in 200 μL of RPMI 10% FBS in the presence 
of UV-irradiated DENV-2 (UV-DENV-2) (MOI equivalent of 1.7) or 
RPMI 10% FBS alone. After 72 hours of incubation at 37°C superna-
tant fluids were removed and assayed for cytokines. Total RNA was 
extracted from cell pellets using TRIzol and assayed for transcription 
factors involved in the immune response by qRT-PCR.
2.8 | Cytokine determinations
Cytokines were determined in the supernatants of stimulated sple-
nocytes using immunoassays for IFN-γ and IL-4 (eBioscience) follow-
ing the manufacturer´s instructions.
2.9 | Quantification of RNA transcripts
The relative quantification of transcription factors mRNA expression 
(T-bet and GATA3) that regulate each T-helper (Th) cell differentia-
tion pathway (Th1, Th2, respectively) was performed by real time 
RT-PCR using TaqMan gene expression assays (Applied Biosystems) 
and the 2−ΔΔCT method.
41 Beta-actin was used as internal control.
2.10 | Statistical analysis
Bar, XY graphs and statistical analyses (mean, standard error, 
and statistical tests) were generated with GraphPad Prism. The 
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Student´s unpaired t test was used to determine statistical signifi-
cance between two treatment groups. The one-way ANOVA and 
Bonferroni´s multiple comparison post-test correction was used to 
evaluate differences amongst multiple groups. Statistical signifi-
cance is depicted in figures: *P < .05, **P < .01.
3  | RESULTS
3.1 | DENV infection in suckling mice
In order to establish a mouse model to study possible mechanisms 
of dengue disease in infants, we started characterizing DENV 
primary infection in immunocompetent suckling mice (Figure 1). 
Three-day-old C57BL/6 and BALB/c mice were infected IP with 
5 × 105 PFU/g of DENV-2 NGC. Control mice were inoculated 
IP with an equal volume of C6/36 cell supernatant. The DENV-2 
strain NGC was used because it has shown a higher ability to infect 
mice compared to other DENV strains.42 Considering that mice are 
weaned approximately 21 post-natal days (PND) and that solid 
feeding starts at 16 PND, viral infection was performed at 3 PND 
and infection was followed until day 8 PI, ensuring that all sam-
ples were collected during the exclusive suckling period. Owing 
to the small size of 3-day-old mice, the implementation of certain 
infection techniques was difficult, such as intracerebral (i.c.), in-
travenous (iv) and subcutaneous (s.c.) inoculation. Therefore, the 
IP route, implementing the age-specific techniques described in 
methodology, was selected as the most appropriate technique to 
infect mice (Figure 2).
First, growth and survival curves were analyzed for DENV-2 
infected mice compared to control mice. A slight growth retar-
dation was observed for infected C57BL/6 pups compared to 
uninfected pups (Figure 3A). Conversely, DENV-2 infection did 
not affect BALB/c mouse growth (Figure 3B). A 100% survival 
rate was observed for both strains of infected mice until day 8 PI 
(Figure 3C,D).
3.2 | Hematological and biochemical determinations
Several studies in DENV patients have reported biochemical altera-
tions, such as transaminitis, increased LDH and CK levels in plasma 
F I G U R E  1   Timeline of DENV infection and determinations in suckling mice. C57BL/6 and BALB/c pups were infected IP with 5 × 105 
PFU/g body weight of DENV-2 NGC or C6/36 cell culture supernatant (control) at 3 PND. Letters indicate the hours post inoculation (HPI) 
at which mice were euthanized for the following determinations: A, Plasma levels of aspartate aminotransferase, alanine aminotransferase 
(ALT), lactate dehydrogenase (LDH), and creatine kinase (CK), and platelet counts; B, Total RNA was extracted from plasma, mesenteric 
lymph nodes, liver, kidney, spleen, small intestine, and brain and viral RNA was quantified using qRT-PCR; C, Liver, kidney, spleen, small 
intestine, and brain were fixed, embedded in paraffin and stained with hematoxylin and eosin (H&E); D, Splenocytes were incubated during 
72 h with DENV-2 antigen or medium, and after centrifugation, IFN-γ and IL-4 were quantified in cell culture supernatants. In addition, total 
RNA in cell pellets was used to determine mRNA expression of T-bet and GATA3. In order to reach minimum volumes of plasma for some 
determinations, blood from 2 mice was pooled
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and thrombocytopenia.43-47 At day 8 PI, DENV-2 infected C57BL/6 
mice showed a significant increase in AST and ALT levels indicating 
liver damage, and elevated LDH and CK levels in plasma suggest-
ing tissue injury compared to control mice (Figure 4A,C,E,G). BALB/c 
mice infected with DENV-2 also exhibited a significant increase in CK 
and a trend towards augmented AST, ALT and LDH levels in plasma 
compared to control mice (Figure 4B,D,F,H). No significant differ-
ences were observed in platelet count in DENV-2 infected mice of 
either strain compared to control mice.
3.3 | Viral detection kinetics in blood and tissues
After DENV-2 IP infection, viremia levels were variable in C57BL/6 
and BALB/c pups up to 168 hours PI. In both mouse strains, viral 
RNA plasma levels peaked at 24 hours PI and again at 72-96 hours 
PI, decreasing thereafter (Figure 5A,B). In C57BL/6 mice, viral 
RNA was differentially detected in mesenteric lymph nodes, kid-
ney and liver. DENV-2 RNA levels were low to undetectable up to 
F I G U R E  2   Intraperitoneal inoculation of suckling mice. Three-day-old C57BL/6 and BALB/c mice were inoculated with 5 × 105 PFU/g 
of DENV-2 or cell supernatant by an inverse IP administration technique. A, Mouse immobilization and location of inoculation site. B, 
Inoculum incision in the subcutaneous level moving forward into cranium-caudal direction and entering the peritoneal cavity for inoculum 
administration
F I G U R E  3   Effect of DENV-2 infection on suckling mouse growth and survival. Growth of C57BL/6 (A) and BALB/c (B) infected and 
control mice until 8 d PI. Survival of C57BL/6 (C) and BALB/c (D) infected and control mice until 8 d PI. Values represent means ± SEM. 
*P < .05, determined by Student's unpaired t test
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168 hours PI in mesenteric lymph nodes and kidney, while viral 
RNA peaked at 17 and 96 hours PI in liver, suggesting transient 
replication (Figure 5C-E). In contrast, viral RNA levels in spleen, 
small intestine and brain of C57BL/6 mice were very low to unde-
tectable. Regarding BALB/c mice, DENV-2 RNA was very low to 
undetectable in solid organs.
3.4 | Histological alterations
In order to analyze possible histological alterations produced by 
DENV-2 infection of suckling mice, histological sections of several 
tissues were performed. At day 8 PI, both strains of infected mice 
showed lymphoid mononuclear infiltrates in liver and intestine, and 
F I G U R E  4   Biochemical parameters at 8 d PI in suckling mice infected with DENV-2. Plasma levels of AST (A, B), ALT (C, D), LDH (E, 
F) and CK (G, H) were determined in C57BL/6 and BALB/c infected and control mice. ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase. Values represent means ± SEM. *P < .05, determined by Student's 
unpaired t test
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lytic focuses in the apical region of intestinal villi (Figure 6). Sections 
of spleen, kidney and brain did not show marked alterations com-
pared to controls. These results suggest that histological damage 
was similar in C57BL/6 and BALB/c pups.
3.5 | Inflammatory response
Previous studies have reported differential innate and adaptive 
immune responses to human pathogens in C57BL/6 and BALB/c 
mice.48-50 Therefore, we evaluated the immune response to DENV-2 
IP infection in suckling C57BL/6 and BALB/c mice by measuring Th1 
and Th2 cytokines and associated transcription factors in DENV-
stimulated mouse splenocytes (Figure 7). For this purpose, spleno-
cytes were isolated from mice infected with DENV-2 or C6/36 cell 
supernatant (control group) at 8 days PI and were then exposed to 
UV-DENV-2 for 72 hours. Splenocytes from infected C57BL/6 mice 
exhibited a significantly increased production of IFN-γ compared to 
control mice (159.0 ± 64.5 pg/mL vs 6.0 ± 2.9 pg/mL, for infected 
and control C57BL/6 mice, respectively, P < .05) (Figure 7A). In con-
trast, splenocytes from infected BABL/c mice showed a low IFN-γ 
production similar to that of control mice. Additionally, relative T-bet 
F I G U R E  5   Virus detection by qRT-PCR in plasma and tissues after DENV-2 infection in suckling mice. C57BL/6 and BALB/c mice 
were infected with DENV-2 IP, and at different times PI (0, 17, 24, 48, 72, 96, 120 and 168 h), mice were euthanized and plasma (A, B), 
mesenteric lymph nodes (C) and organs (D, E) were collected. Total RNA was extracted from tissues and DENV RNA was detected by qRT-
PCR. Abbreviations: LN, lymph node. Values represent means ± SEM. *P < .05, **P < .01 determined by one-way ANOVA (dashed line) and 
Bonferroni's multiple comparison post-test (solid line). Dotted lines show limits of detection
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mRNA expression was higher in C57BL/6 mice compared to that 
of BALB/c mice (Figure 7B). Interleukin-4 production in splenocyte 
supernatants from both mouse strains was not significantly differ-
ent in infected and control groups (Figure 7C). Furthermore, relative 
GATA3 mRNA expression was similar in C57BL/6 and BALB/c mice 
(Figure 7D). A 6-fold higher IFN-γ/IL-4 ratio was found in C57BL/6 
mice compared to BALB/c mice (30.28 ± 14.83 vs 4.96 ± 2.13, for 
C57BL/6 and BALB/c mice, respectively), suggesting a trend to-
wards a Th1 bias in C57BL/6 mice.
4  | DISCUSSION
Clinical and experimental evidence have shown that humoral and 
cellular immunity play a role in both the protection and pathogenesis 
of dengue illness. Given the immunological immaturity of infants and 
their vulnerability to severe outcomes during primary infection with 
DENV, we sought to establish a model that recapitulates important 
aspects of human DENV illness in immunocompetent neonatal mice 
in service of better understanding pathogenesis in this uniquely vul-
nerable population.
C57BL/6 and BALB/c pups were not equally susceptible to in-
fection with DENV-2 NGC. While the C57BL/6 pups had significant 
increases in AST and ALT, LDH and CK levels, extended viremia and 
dissemination to organs accompanied by infiltrates in the liver and 
intestine as well as damage to intestinal villi, BALB/c pups had de-
tectable viremia up to 96 hours PI, and increased CK compared to 
controls. At 8 days PI infiltrates were detected in the liver and in-
testine but virus was undetectable in these organs at this point in 
time. The immune response of DENV-infected C57BL/6 pups had a 
marked Th1 bias compared to BALB/c pups.
Similarly, adult BALB/c mice infected IP with a non-mouse 
adapted strain of DENV-2 have been reported to suffer liver injury 
corresponding with increased serum AST and ALT despite very low 
viremia.51 Another group has observed increased ALT and AST, de-
creased hematocrit and increased platelet count after IP infection 
of BALB/c adults with brain suspension containing DENV-3 pas-
saged intracerebrally in weaning and then adult BALB/c mice. This 
adapted strain was also used to infect C57BL/6 adults, resulting in 
F I G U R E  6   Histopathology in suckling mice after DENV-2 infection. Cross sections of various tissues of infected and control C57BL/6 
and BALB/c mice at 8 d PI. Arrows indicate lymphoid mononuclear infiltrates in liver and small intestine and lytic focuses in the apical region 
of intestinal villi in DENV-2 infected mice. Magnification: 200× for liver and kidney, and 100× for spleen, small intestine and brain. H&E 
staining
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more severe disease, elevated liver enzymes, thrombocytopenia, 
progressive drop in blood pressure and dose-dependent lethality. 
In C57BL/6 mice, cytokine levels of IFN-γ, IL-12 and IL-18 were 
associated with severity.32 The outcomes of infection described 
in our study for suckling BALB/c and C57BL/6 mice are consis-
tent with previously published outcomes in adult mice of the same 
strain.
It has been reported that C57BL/6 adult mice inoculated IP with 
a neuroadapted strain of DENV-1 had detectable viremia 4-16 days 
PI, with a peak at 10 days PI, coinciding with a peak in viral repli-
cation in the brain. Virus disseminated to spleen, liver and kidneys, 
all of which fell to undetectable levels by 16 days PI. The peak of 
viremia coincided with decreased platelet levels. Throughout the 
infection, mice had increased AST and ALT as well as immune in-
filtration in liver and increased Th1 associated cytokines IL-12 and 
IL-18.33 The present study reports a number of markers of disease 
in C57BL/6 pups shared by C57BL/6 adults, such as increased liver 
enzymes accompanied by immune infiltrates and viral dissemination 
to liver and kidney.
In our study we used a mouse-adapted strain of DENV-252 to in-
fect immunocompetent suckling mice by IP inoculation. Even though 
DENV-2 NGC has been reported to be neurovirulent in mice,42 viral 
RNA was neither found in brain nor were alterations observed in his-
tological sections of this tissue by IP inoculation of virus in suckling 
C57BL/6 and BALB/c mice. In contrast, significant levels of viral RNA 
were detected in liver of C57BL/6 pups consistent with the finding 
of lymphoid mononuclear infiltrates in this tissue.
Route of infection is a determinant of early cell tropism and the 
course of infection.53 For DENV and other vector-borne viruses, 
using the natural route of infection is often unfeasible and exper-
imental methods may approximate natural infection in humans or 
select alternative routes that may better reflect other facets of in-
fection. In our model, C57BL/6 and BALB/c pups infected IP with 
DENV-2 showed 100% survival. Conversely, other mouse models in 
immunocompetent suckling mice using i.c. inoculation of DENV have 
shown lower survival rates and have been used to study virulence 
of DENV strains or antiviral agents.54-56 Furthermore, immunocom-
promised suckling mouse models of DENV that used the s.c. or iv 
routes of infection have exhibited lower survival rates than our im-
munocompetent mouse model, mainly due to the lack of IFN-I and/
or IFN-II signaling pathways or to the enhanced effect of maternal 
antibodies.38,39,57
In previous studies, C57BL/6 and BALB/c mice have shown 
a distinct immune profile after infection with different human 
pathogens.48-50 Concerning our model of DENV primary infection, 
C57BL/6 pups exhibited a Th1 bias evidenced by a 6-fold higher 
IFN-γ/IL-4 ratio compared to BALB/c pups. Increased Th1 cytokines 
have also been detected in adult C57BL/6 mice after DENV primary 
infection32,33 and a role for IFN-γ in resistance against infection has 
been reported.32
Interestingly, a number of groups have developed models with 
young mice, highlighting the importance of immunological immatu-
rity and maternally acquired antibodies in DENV immune response. 
In one model of neuroinfection using an i.c. passaged DENV-4 strain, 
F I G U R E  7   Immune response in suckling mice after DENV-2 infection. C57BL/6 and BALB/c mice were infected IP with DENV-2 or C6/36 
cell supernatant (control). At 8 d PI, splenocytes were isolated from infected and control mice and stimulated with UV-DENV-2 during 72 h. 
A, C, Cytokine levels were measured in cell supernatants by immunoassay. B, D, Total RNA was extracted from cell pellets and relative 
quantity (QR) of transcription factor mRNA corresponding to Th1 and Th2 cell pathways was determined. Values represent means ± SEM. 
*P < .05, determined by one-way ANOVA (dashed line) and Bonferroni's multiple comparison post-test (solid line). Dotted lines show limits of 
detection
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BALB/c pups inoculated up to 7 PND suffered encephalitis and 
death, while mice infected 14 and 21 PND survived. This strain of 
DENV-4 was detectable in brain in all mice assayed 6 days PI, but 
generally did not disseminate to organs.58
Work done in weaning and young immunocompromised mice 
highlights the versatility of experimental designs of a suckling mouse 
model. In experiments comparing primary infection with clinical DENV 
isolates in young AG129 mice born to DENV-immune and naive moth-
ers found that mice born to DENV-immune mothers developed vascu-
lar leakage and lethal disease, while both groups had transient viremia, 
increased liver enzymes, cytokine upregulation and viral dissemina-
tion to lymph nodes, spleen, intestine and liver.38 The same group 
has recapitulated many of these findings in the less immunocompro-
mised A129, which lack type I IFN-signaling pathway compared to the 
AG129 which lack type I and II IFN-signaling pathways.39,57
In conclusion, we present an immunocompetent mouse model of 
DENV-2 primary infection in suckling mice that reproduces certain as-
pects of dengue disease observed in humans and that could be used to 
further study age-related mechanisms of dengue pathogenesis as well 
as the role of passively transferred anti-DENV antibodies in DENV 
disease severity. Additionally, the results of this study demonstrate 
that the technical refinement of IP viral inoculation was safe, effective 
and minimized harm in C57BL/6 and BALB/c pups; it is an efficient 
alternative for administration of substances to suckling mice.
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